platinum has been researched along with Cystadenocarcinoma, Serous in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.82) | 18.2507 |
| 2000's | 7 (12.73) | 29.6817 |
| 2010's | 33 (60.00) | 24.3611 |
| 2020's | 14 (25.45) | 2.80 |
| Authors | Studies |
|---|---|
| Davidson, B; Elstrand, MB | 1 |
| Fang, F; Lai, T; Metcalfe, TX; Nephew, KP; O'Hagan, HM; Sriramkumar, S; Zong, X | 1 |
| Dong, L; Li, N; Wang, T; Wu, L; Yao, H; Ying, J; Yuan, G | 1 |
| Brennan, DJ; Doran, P; Glennon, K; Jeronimo, C; Lynch, L; Martin, T; Metoudi, M; Moran, B; Perry, AS; Salta, S; Shaw, J; Silva, R; Slattery, K; Treacy, A | 1 |
| Aghajanian, C; Chi, DS; Chui, MH; Girshman, J; Gordhandas, S; Grisham, RN; Iasonos, A; Kahn, RM; Laibangyang, A; Long Roche, K; Manning-Geist, BL; Nemirovsky, D; Zivanovic, O | 1 |
| Su, R; Su, X; Wang, Z; Wu, X; Yang, L | 1 |
| Harada, H; Izumi, H; Koi, C; Kurita, T; Murakami, M; Shibahara, M; Yoshino, K | 1 |
| Akkus, MH; Aksel, B; Ates, O; Dogan, M; Oner, I; Yuksel, C | 1 |
| Fan, S; Zhang, L; Zhang, X; Zhang, Z | 1 |
| Hu, R; Liu, R; Zeng, Y; Zhang, W; Zhou, HH | 1 |
| Adorni, M; Ballabio, S; Beltrame, L; Benvenuto, G; Bignotti, E; Calura, E; Ceppi, L; D'Incalci, M; Delle Marchette, M; Donati, F; Fruscio, R; Grassi, T; Marchini, S; Martini, P; Odicino, F; Paracchini, L; Perego, P; Ravaggi, A; Romani, C; Romualdi, C; Sales, G; Sartori, E; Todeschini, P; Tognon, G; Zanotti, L | 1 |
| Avgeris, M; Braicu, I; Dorn, J; Dreyer, T; Loverix, L; Magdolen, V; Magkou, P; Mahner, S; Mavridis, K; Michaelidou, K; Obermayr, E; Panoutsopoulou, K; Reinthaller, A; Scorilas, A; Sehouli, J; Vergote, I; Zeillinger, R | 1 |
| Chen, K; Cheng, X; Dai, H; Li, H; Shi, T; Sun, M; Wang, M; Wei, Q | 1 |
| Hoare, JI; Lockley, M; Martin, SA; Metcalf, S; Nicolini, F; Saxena, J; Silva, VL | 1 |
| Chen, A; Chen, Z; Kanetsky, PA; Permuth, JB; Reid, BM; Saglam, O; Sellers, TA; Vyas, S | 1 |
| Fang, L; Li, P; Wang, H | 1 |
| Blyth, K; Coffelt, S; Dowson, S; Farquharson, M; Kim, J; Kruspig, B; Mason, S; Matzuk, M; McNeish, IA; Murphy, D; Port, J; Stevenson, D; Walton, JB | 1 |
| Clamp, AR; Edmondson, RJ; Evans, DGR; Jayson, GC; Morgan, RD | 1 |
| Braicu, I; Darb-Esfahani, S; Ganapathi, MK; Ganapathi, RN; Lanchbury, JS; Patel, JN; Reid, J; Sehouli, J; Solimeno, C; Timms, KM; Tshiaba, P | 1 |
| du Bois, A; Fielding, A; Friedlander, M; Gourley, C; Ledermann, J; Lowe, ES; Mann, H; Matei, D; Matulonis, U; McMurtry, EL; Meier, W; Parry, D; Rowe, P; Rustin, G; Safra, T; Scott, C; Selle, F; Shapira-Frommer, R; Shirinkin, V; Spencer, S; Vergote, I | 1 |
| Beach, JA; Bowtell, DDL; Christie, EL; Freimund, AE | 1 |
| Chen, L; Cheng, X; Dong, C; Liu, F; Liu, G; Liu, L; Liu, Z; Ren, H; Wu, A; Zheng, Y | 1 |
| Arakawa, A; Chan, MWY; Katsushima, K; Kondo, Y; Lai, HC; Lin, RI; Mase, S; Shinjo, K; Sugiura-Ogasawara, M; Takahashi, S; Totani, H | 1 |
| Deng, JL; Li, TL; Liu, YZ; Sun, H; Wan, ZR; Wang, G; Zeng, Y; Zhang, HB; Zhang, R; Zhu, YS | 1 |
| Bender, DP; Devor, EJ; Gonzalez-Bosquet, J; Goodheart, MJ; Leslie, KK; McDonald, ME; Newtson, AM; Salinas, EA; Smith, BJ; Thiel, KW | 1 |
| Canzonieri, V; Cecchin, E; De Mattia, E; Gagno, S; Garziera, M; Giorda, G; Montico, M; Poletto, E; Roncato, R; Scalone, S; Sorio, R; Toffoli, G | 1 |
| Cai, Y; Hou, Y; Li, K; Rong, Z; Song, W; Wang, W; Xie, H; Xu, H | 1 |
| Barnett, JC; Havrilesky, LJ; Ledermann, JA; Myers, ER; Peterson, BL; Secord, AA | 1 |
| Lv, X; Pan, ZH; Su, A; Zhang, J; Zhou, QM | 1 |
| Brown, R; Dai, W; Masrour, N; Paul, J; Siddiqui, N; Zeller, C | 1 |
| Duvillard, P; Gouy, S; Leary, A; Ledoux, F; Lhommé, C; Morice, P; Pautier, P; Petrella, MC; Tazi, Y; Uzan, C | 1 |
| Cui, Y; Gao, Y; Li, J; Li, M; Liu, H; Tian, Y; Zhang, Y | 1 |
| Liu, LH; Liu, YH; Xu, L; Yang, H | 1 |
| Brachova, P; Button, AM; Carlson, MJ; Dai, D; Devor, EJ; Goodheart, MJ; Leslie, KK; Mott, SL; Mueting, SR; Thiel, KW | 1 |
| Braicu, I; Olschewski, J; Sehouli, J; Vasconcelos, I | 1 |
| Jansaka, N; Suprasert, P | 1 |
| Angioli, R; De Felice, F; Giorgini, M; Iadarola, R; Lecce, F; Marchetti, C; Monti, M; Musella, A; Muzii, L; Palaia, I; Panici, PB; Perniola, G; Vertechy, L | 1 |
| Achatz, MI; Baiocchi, G; da Costa, AA; Guimarães, AP; Mantoan, H; Saito, A; Sanches, S; Valadares, CV | 1 |
| Chen, DT; Chen, Z; Cheng, JQ; Fulp, WJ; Georgeades, C; Lancaster, JM; Magliocco, A; Permuth-Wey, J; Reid, BM | 1 |
| Abiko, K; Baba, T; Chikuma, S; Hamanishi, J; Honjo, T; Hosoe, Y; Ikeda, T; Kanai, M; Kawaguchi, A; Konishi, I; Mandai, M; Matsumoto, S; Matsumura, N; Minami, M; Mori, Y; Morita, S; Murayama, T; Shimizu, A; Ueda, A; Yamaguchi, K; Yokode, M | 1 |
| Cianci, S; Costantini, B; De Iaco, P; Fagotti, A; Perrone, M; Petrillo, M; Ronsini, C; Scambia, G | 1 |
| Barni, T; Botta, C; Camastra, C; De Marco, C; Di Cello, A; Di Vito, A; Donato, G; Franco, R; Malara, N; Mignogna, C; Morelli, M; Presta, I; Rizzuto, A; Salvino, A; Staropoli, N; Tagliaferri, P; Tassone, P | 1 |
| Li, L; Wang, Q; Wu, WJ; Zhang, W | 1 |
| Ansari, J; Buckley, L; Fernando, I; Tanguay, JS | 1 |
| Farshchi-Heydari, S; Howell, SB; Jandial, DD; Messer, K; Pu, M | 1 |
| Boren, TP; Miller, DS | 1 |
| Foretová, L; Fridrichová, P; Laco, J; Melichar, B; Papajík, T; Simkovič, M | 1 |
| Bertoni, F; Catapano, CV; Colombo, N; Del Conte, G; Gadducci, A; Hess, D; Katsaros, D; Mancari, R; Marsoni, S; Parma, G; Rinaldi, A; Scambia, G; Sessa, C; van de Velde, H; Vitali, A | 1 |
| Agarwal, R; Blagden, S; Diamantis, N; Gabra, H; Shaboodien, R | 1 |
| Bamias, A; Diakomanolis, E; Dimopoulos, AM; Markaki, S; Michalas, S; Milingos, S; Papadimitriou, C; Protopapas, A | 1 |
| Fujii, K; Kikuchi, Y; Kita, T; Okamoto, S; Sasaki, N; Takano, M | 1 |
| Bast, RC; Clark, EA; Cliby, WA; Damokosh, AI; Gershenson, D; Hartmann, LC; Hoersch, S; Iartchouk, N; Kalli, KR; Kaufmann, SH; Lillie, J; Linette, GP; Lu, KH; Ross, JS; Shridhar, V; Smith, DI; Stec, J | 1 |
| Angioli, R; Basile, S; Bellati, F; Benedetti Panici, P; De Vivo, A; Manci, N; Muzii, L; Perniola, G | 1 |
| Chang, J; Fisher, C; Fryatt, I; Gore, ME; Ponder, B | 1 |
| Isonishi, S; Saitou, M; Tanaka, T; Yasuda, M | 1 |
4 review(s) available for platinum and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
Topics: Cell Line, Tumor; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Neoplasm Grading; Ovarian Neoplasms; Platinum; Prognosis; RNA, Long Noncoding; RNA, Messenger | 2018 |
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
Topics: Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2018 |
Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer.
Topics: Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Taxoids | 2018 |
A meta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with invasive implants.
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Drug Implants; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Treatment Outcome | 2015 |
4 trial(s) available for platinum and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Capsules; Cystadenocarcinoma, Serous; Disease-Free Survival; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Middle Aged; Mutation; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Treatment Outcome; Young Adult | 2018 |
Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Rate | 2015 |
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Topics: Adenocarcinoma, Clear Cell; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Cohort Studies; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prognosis; Programmed Cell Death 1 Receptor; Salvage Therapy; Survival Rate | 2015 |
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CA-125 Antigen; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2012 |
47 other study(ies) available for platinum and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions.
Topics: Biomarkers, Tumor; Carcinoma; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Platinum; Pleural Effusion, Malignant; Prognosis; Retrospective Studies | 2022 |
Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment.
Topics: Carcinoma, Ovarian Epithelial; Cell Line; Cell Line, Tumor; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Single-Cell Analysis; Transcriptome | 2022 |
Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma.
Topics: Cystadenocarcinoma, Serous; Humans; Mutation; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Prevalence; Prognosis; Recombinational DNA Repair | 2022 |
Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Epigenomics; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2023 |
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cystadenocarcinoma, Serous; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Retrospective Studies | 2023 |
Single-cell RNA-sequencing analysis reveals divergent transcriptome events between platinum-sensitive and platinum-resistant high-grade serous ovarian carcinoma.
Topics: Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; DNA-Binding Proteins; Female; Humans; Ovarian Neoplasms; Platinum; RNA; Transcriptome; Tumor Microenvironment | 2023 |
Association of UBE2L6 and ABCB6 Expression With Platinum Resistance in Serous Ovarian Carcinoma.
Topics: ATP-Binding Cassette Transporters; Carcinoma, Ovarian Epithelial; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Prognosis; Ubiquitin-Conjugating Enzymes | 2023 |
HIPEC in Ovarian Cancer: When and to Whom?
Topics: Cisplatin; Cystadenocarcinoma, Serous; Female; Fever; Humans; Hyperthermic Intraperitoneal Chemotherapy; Middle Aged; Ovarian Neoplasms; Platinum | 2023 |
Identification of modules and hub genes associated with platinum-based chemotherapy resistance and treatment response in ovarian cancer by weighted gene co-expression network analysis.
Topics: Antineoplastic Agents; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Ovarian Neoplasms; Platinum; Prognosis | 2019 |
Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study.
Topics: Cohort Studies; Computational Biology; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy; Kaplan-Meier Estimate; Lymphocyte Subsets; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Support Vector Machine; Treatment Outcome | 2020 |
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
Topics: Adult; Aged; Cyclic GMP-Dependent Protein Kinase Type I; Cystadenocarcinoma, Serous; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Middle Aged; Myosin-Light-Chain Phosphatase; Neoplasm Grading; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cohort Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Disease Progression; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Ovarian Neoplasms; Platinum; Prognosis; Survival Analysis; Treatment Outcome; Up-Regulation | 2020 |
Potentially functional variants in nucleotide excision repair pathway genes predict platinum treatment response of Chinese ovarian cancer patients.
Topics: Asian People; Biomarkers, Tumor; Cell Cycle Proteins; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Genotype; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Polymorphism, Single Nucleotide; Prognosis; ROC Curve; Transcription Factors | 2020 |
Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chloroquinolinols; Cisplatin; Cystadenocarcinoma, Serous; DNA Damage; Drug Resistance, Neoplasm; Female; Humans; Mice, Transgenic; Ovarian Neoplasms; Platinum | 2021 |
Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
Topics: Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Female; Humans; Middle Aged; Neoplasm Grading; Ovarian Neoplasms; Platinum | 2021 |
CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.
Topics: Animals; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Cell Survival; CRISPR-Cas Systems; Cystadenocarcinoma, Serous; Disease Models, Animal; Female; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Grading; Neurofibromin 1; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; PTEN Phosphohydrolase; Survival Rate; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2017 |
Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Topics: Adult; Aged; BRCA1 Protein; BRCA2 Protein; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Disease Progression; DNA Methylation; Female; High-Throughput Nucleotide Sequencing; Homologous Recombination; Humans; Loss of Heterozygosity; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Sequence Analysis, DNA; Young Adult | 2018 |
Seven Genes Based Novel Signature Predicts Clinical Outcome and Platinum Sensitivity of High Grade IIIc Serous Ovarian Carcinoma.
Topics: Cell Movement; Cell Proliferation; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Platinum; Proportional Hazards Models; Real-Time Polymerase Chain Reaction; Transcriptome | 2018 |
ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer.
Topics: Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cystadenocarcinoma, Serous; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Recurrence, Local; Platinum; Prognosis; Tumor Suppressor Proteins | 2019 |
Polymorphisms in IGF2/H19 gene locus are associated with platinum-based chemotherapeutic response in Chinese patients with epithelial ovarian cancer.
Topics: Adult; Aged; Carcinoma, Ovarian Epithelial; China; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Genetic Association Studies; Genotype; Haplotypes; Humans; Insulin-Like Growth Factor II; Middle Aged; Platinum; Polymorphism, Single Nucleotide; RNA, Long Noncoding | 2019 |
Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer.
Topics: Cluster Analysis; Computational Biology; Cystadenocarcinoma, Serous; Databases, Genetic; DNA Methylation; Epigenesis, Genetic; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Middle Aged; Mutation; Neoplasm Staging; Ovarian Neoplasms; Platinum; Unsupervised Machine Learning | 2019 |
New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
Topics: Adult; Aged; Aged, 80 and over; Cystadenocarcinoma, Serous; Female; Genetic Heterogeneity; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Mutation Rate; Neoplasm Staging; Ovarian Neoplasms; Platinum; Treatment Outcome; Tumor Suppressor Protein p53 | 2019 |
Integrative prognostic subtype discovery in high-grade serous ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cystadenocarcinoma, Serous; Desmosomal Cadherins; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Ovarian Neoplasms; Ovary; Platinum; Prognosis; Proteomics | 2019 |
Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Survival Rate | 2013 |
Salvage therapy of gemcitabine plus endostar significantly improves progression-free survival (PFS) with platinum-resistant recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endostatins; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis; Recombinant Proteins; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CpG Islands; Cystadenocarcinoma, Serous; Disease Progression; DNA Methylation; Female; Humans; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Promoter Regions, Genetic; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum; Retrospective Studies; Treatment Outcome | 2014 |
Downregulation of HNF1 homeobox B is associated with drug resistance in ovarian cancer.
Topics: Cell Line, Tumor; Cystadenocarcinoma, Serous; Down-Regulation; Drug Resistance, Neoplasm; Female; Hepatocyte Nuclear Factor 1-beta; Humans; MicroRNAs; Ovarian Neoplasms; Platinum | 2014 |
Efficacy of permanent iodine-125 seed implants and gemcitabine chemotherapy in patients with platinum- resistant recurrent ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Brachytherapy; Chemoradiotherapy; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Tomography, X-Ray Computed | 2014 |
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Topics: Adult; Aged; Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Taxoids; Tumor Suppressor Protein p53 | 2015 |
Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Survival Rate; Tertiary Care Centers | 2014 |
Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Risk Factors; Survival Rate | 2015 |
STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Case-Control Studies; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Polymorphism, Single Nucleotide; Receptor, Notch1; STAT3 Transcription Factor | 2016 |
Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aurora Kinase A; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis | 2016 |
[Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Topics: Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; China; Computational Biology; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Proteomics; ROC Curve; Treatment Outcome | 2016 |
Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment.
Topics: CA-125 Antigen; Carcinoma, Papillary; Cohort Studies; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model.
Topics: Animals; Carboplatin; Cell Line, Tumor; Cisplatin; Cystadenocarcinoma, Serous; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Platinum; Transplantation, Heterologous | 2009 |
Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Papillary; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Taxoids | 2010 |
Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: report of two cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Fatal Outcome; Female; Genes, BRCA1; Heterozygote; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Neoplasms, Glandular and Epithelial; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Platinum | 2012 |
Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Patient Selection; Platinum; Prognosis; Survival Rate | 2013 |
The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Endometrioid; Cathepsin D; Cyclophosphamide; Cystadenocarcinoma, Serous; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Survival Analysis; Tumor Suppressor Protein p53 | 2004 |
[Clinical study on the efficacy of weekly paclitaxel administration for platinum-resistant epithelial ovarian carcinoma].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Serous; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Quality of Life | 2004 |
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Platinum; Survival Rate | 2005 |
Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Observation; Ovarian Neoplasms; Platinum; Prognosis; Prospective Studies | 2007 |
A matched control study of familial epithelial ovarian cancer: patient characteristics, response to chemotherapy and outcome.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Child; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Prognosis; Survival Rate | 1995 |
Mitochondria in platinum resistant cells.
Topics: Adenocarcinoma, Clear Cell; Apoptosis; Cystadenocarcinoma, Serous; Cytochrome c Group; Drug Resistance, Neoplasm; Female; Humans; Membrane Potentials; Mitochondria; Ovarian Neoplasms; Platinum; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2001 |